Dev ParameshvanChief Human Resources Officer
Portrait of Dev Parameshvan

The journey so far

Dev Parameshvan

Chief Human Resources Officer · India

A pharmaceutical company reveals its priorities in the careers it makes possible.

An experienced analyst should not have to become a reluctant line manager to earn recognition for deeper technical work. A quality leader should know who will hear a disagreement when the production calendar becomes difficult. A new manufacturing line needs more than an approved headcount. These questions connect careers, authority and operating capacity. They are where I have spent much of my working life, first in factory personnel and now as the fictional CHRO of Anvethra Pharmaceuticals.

Our India-based business develops and manufactures oral-solid formulations. It employed 4,600 people at the end of March 2026 across three manufacturing locations, a development centre and commercial functions. I lead seventy-four people colleagues through six direct reports. My responsibility is to connect the organisation and employment decisions with the technical work, without pretending that the people function can make a scientific assessment or release a batch.

I am interested in the gap between an approved organisation chart and the experience of holding a role. Does a specialist have a credible future? Can a supervisor decline work that exceeds the capability available? Does the quality function have access to the person who can resolve an organisational disagreement? My record includes decisions that cost more or took longer than planned, and one reward experiment I helped reverse. Those consequences are more useful than a broad claim that culture improved.

Technical progression acquired an actual pay and role structure

A 2021 specialist-career review covered 84 formulation and analytical colleagues. Eighteen moved into assessed specialist grades without taking line-management duties. The approved annual pay effect was ₹1.26 Cr. The remaining sixty-six stayed in their current grades with written feedback; the exercise was not presented as a universal promotion.

An expansion timetable changed when experience could not be copied

For a 2023 line expansion, a proposed transfer of twenty-four experienced colleagues would have weakened the existing unit. We agreed twelve transfers and twelve external hires, with ₹2.4 Cr for staged overlap and preparation. The revised start moved six weeks. Technical leaders retained responsibility for authorising work.

An incentive was withdrawn when its signal proved harmful

In 2014, I supported an attendance-linked supervisor award. Employee discussions showed that it discouraged timely reporting of illness. We withdrew that criterion, reassessed forty-one awards and changed thirteen decisions. The ₹19 lakh correction was recorded as the cost of our original design, not a workforce success statistic.

Current focus

My 2026 review examines twelve specialist appointments made during the previous two years. Nine have written evidence of the technical contribution expected at their grade; three need clearer role definitions. I am working with functional leaders on those three cases before proposing another expansion of the career structure. A title should create a usable responsibility, not merely settle a retention conversation.

Conversations I welcome

I am open to a people-leadership or advisory mandate in a pharmaceutical business willing to examine the relationship between technical authority, careers and investment decisions. I would consider a first external board appointment with an appropriate induction and a clearly defined contribution. For speaking, I prefer a working discussion of one employment decision and its consequences to a general address on inspiration.

A pharmaceutical company reveals its priorities in the careers it makes possible.

I began in a factory personnel office where the shift register was more familiar to me than the product catalogue.

Open to
  • Board appointments
  • Advisory roles
  • Speaking invitations
  • Executive opportunities
  1. 4,600

    Group employees

    31 March 2026; company scale

  2. 74

    People-function colleagues

    Six direct reports; October 2026

  3. ₹31 Cr

    Delegated annual expense

    FY 2027 people function; excludes group payroll

The compass

I pay attention to what happens to the person who gives an inconvenient technical answer. A company can praise expertise while making promotion depend on leaving it behind. My work is to make employment choices consistent with the responsibilities the business says it values, and to acknowledge where our own people systems have sent a different message.

The route

Waypoints of a career.

  1. Waypoint 01 · Jun 1991 — Aug 1996

    Personnel Officer

    Sarunvitha Formulations

    I began with factory records, shift queries and follow-up on unanswered employment questions.

  2. Waypoint 02 · Sep 1996 — Mar 2003

    Personnel Manager

    Sarunvitha Formulations

    I moved employment questions into operating discussions before the final timetable was agreed.

  3. Waypoint 03 · Apr 2003 — Dec 2009

    Head of People, Hyderabad Manufacturing

    Anvethra Pharmaceuticals

    I worked with production and quality colleagues to define the experience behind the staffing plan.

  4. Waypoint 04 · Jan 2010 — Jun 2018

    Vice President, People and Organisation

    Anvethra Pharmaceuticals

    I brought site employment frameworks into a group remit and learned to question the incentives our own function designed.

  5. Waypoint 05 · Jul 2018 — Present

    Chief Human Resources Officer

    Anvethra Pharmaceuticals

    I connect specialist careers, technical authority and staffing investment across the company.

Expeditions

Into difficult terrain, and back with results.

01

Paying for specialist contribution without inventing managerial duties

In 2021, Anvethra Pharmaceuticals reviewed the progression of eighty-four formulation and analytical colleagues. Several experienced specialists had reached a grade where the obvious next move involved line management. Some wanted that responsibility; others wanted to deepen their technical work. Development leaders were using retention exceptions to bridge the gap, but those exceptions did not explain what a more senior specialist was expected to contribute. As CHRO, I proposed a parallel specialist framework with assessed responsibilities and corresponding pay ranges. Technical leaders defined the evidence: complexity of work, the quality of review, contribution to methods and development of others. I did not score the science. My team examined consistency, documented the role and prepared the employment implications. Finance questioned whether the framework would create a general expectation of promotion. Some managers worried about senior specialists earning more without taking responsibility for a larger team. We addressed those objections by publishing the distinction between technical contribution and supervisory scope. Eighteen colleagues were appointed to assessed specialist grades, with an approved annual pay effect of ₹1.26 Cr. Sixty-six remained in their existing grades and received individual feedback. The decision required time from senior technical reviewers, not only a revised job-description document. We also made clear that a specialist title did not automatically confer every form of technical authorisation. The result was a usable alternative to compulsory management progression for that group. It did not prove a reduction in attrition or improvement in product outcomes. Some colleagues were disappointed and challenged the assessment. Those conversations were necessary because a credible framework must explain a decision that is not favourable. I would have prepared the feedback process earlier; the first round gave too much attention to the successful appointments. The lesson was that a technical career path needs evidence, pay and ongoing work that justify the grade, rather than a title designed solely to end a difficult retention discussion.

02

Giving a quality responsibility an organisational route to be heard

A 2019 organisation review at Anvethra identified a practical ambiguity. Site quality heads had defined technical responsibilities, but their people reviews and staffing requests were handled mainly within the local operating hierarchy. The group quality director could discuss technical matters, while some employment decisions reached that function late. I did not interpret this as proof that any technical decision had been compromised. It was an organisational dependency that deserved attention before a serious disagreement tested it. I worked with the group quality director and site leaders on a clearer arrangement. The proposal gave the group quality function a formal role in appointments and performance reviews for the site quality heads, together with a direct escalation route for unresolved staffing and role-authority issues. Plant leaders objected that another approval layer could slow decisions and blur local accountability. Their concern was legitimate: a second reporting line can create delay without adding useful judgement. We therefore specified which decisions required technical functional input and which remained local management responsibilities. The chief executive approved the arrangement. It covered three site quality-head positions and included quarterly conversations about the operation of the reporting relationship. Six staffing or role-definition matters used the new route in the first year; four were resolved through revised responsibilities or resources, while two remained under review at year end. I reported the unresolved matters rather than equating access with resolution. My contribution was the employment architecture and the discipline of explaining who could decide. The quality director retained technical authority, and the arrangement did not make the people function a route for overruling a quality judgement. We accepted additional coordination time to make the responsibility more workable. Looking back, I would have documented the expected response times at the start. Access to a senior person is valuable, but an unresolved request can still become a practical constraint when nobody knows when it will be considered.

03

Revising an expansion when the existing unit still needed its experienced people

The staffing proposal for a 2023 manufacturing-line expansion assumed that twenty-four experienced colleagues would transfer from an established unit. The new unit would receive people familiar with the company’s ways of working, and the group headcount plan would look economical. The existing unit’s leaders challenged the assumption. Losing the full group together would leave gaps in supervision and technical experience that a replacement recruitment list did not adequately describe. I asked the operations and quality leaders to distinguish the positions required from the experience needed at each stage. My team examined the proposed transfers with the individuals and the managers responsible for the work they would leave. We did not treat an internal move as automatically easier for the employee or costless for the company. The alternative plan combined twelve transfers with twelve external hires, sequenced around preparation and authorised work. Finance challenged the additional overlap expense and the effect on the investment timetable. The approved plan provided ₹2.4 Cr for staged overlap and preparation, and moved the planned line start by six weeks. The executive team accepted that trade-off after reviewing the staffing dependencies. Technical leaders retained responsibility for deciding when people could carry out particular work. A filled position in my report was not labelled as operational authorisation. The twelve transfers and twelve hires were completed under the revised plan. That is a staffing outcome, not a claim that the people intervention established manufacturing quality or commercial success. The existing unit kept more of its experienced team during the transition, while the new unit received a more credible sequence of support. I would have put the experience dependencies into the investment discussion sooner. By the time the staffing request arrived, the original timetable had already acquired authority. The lasting change was to require an explicit account of what internal transfers would remove from the sending operation before counting them as capacity for an expansion.

04

Reversing an attendance award after employees described its hidden pressure

In 2014, while vice president for people and organisation, I supported a supervisor award that gave substantial weight to uninterrupted attendance within the team. We believed the measure would recognise dependable staffing and was easy to verify. Employee discussions subsequently revealed a problem we had not examined carefully enough: some people delayed reporting illness because they did not want to damage their supervisor’s result. The award was sending a message that conflicted with the openness we expected about fitness for work. My initial response had been to improve the explanation of the scheme. Listening to employees and occupational-health colleagues changed that view. A clearer communication could not remove the incentive embedded in the measure. I recommended withdrawing the attendance criterion and reviewing the awards already assessed. Operations leaders were concerned that this would undermine confidence in a programme they had introduced in good faith. Finance asked how far retrospective correction should extend. We reviewed forty-one award decisions from the affected period and changed thirteen, with ₹19 lakh in correction payments and review costs. The company explained why the measure had been removed without identifying individual health circumstances. Relevant health decisions remained with appropriately qualified professionals; the reward review did not attempt to judge them. We accepted the cost and the embarrassment of correcting a design the people function had supported. I cannot infer a subsequent health outcome from that change, and I would not use illness reports as a convenient success measure. The evidence was that the original criterion had created an unwanted pressure, and that affected award decisions were reconsidered. My own learning was to ask employees how a proposed measure would feel in a difficult week, not only how it would appear in a management report. We later required that discussion before launching a people incentive. The process is slower, but it is preferable to discovering the behavioural consequence only after colleagues have borne it.

05

Making an acquisition’s grade differences discussable before harmonising them

In 2017, Anvethra brought a smaller formulation-development team into its organisation. The employment review covered 136 colleagues whose titles and grades did not map neatly to the group structure. A quick harmonisation would have simplified administration, but it risked treating similar titles as equivalent work. Several specialists carried broader technical responsibilities than their old grade suggested, while some managerial titles described coordination rather than formal people authority. I led the employment workstream with the development director. We documented actual responsibilities before proposing a grade mapping and held individual conversations where the change was material. The business sponsor wanted a rapid common structure; finance wanted a bounded cost. Employees wanted to know whether the acquisition would change their role, pay or prospects. We chose a staged review, retaining existing pay while the work was assessed, rather than announce a universal equivalence on the first day. Of the 136 colleagues, 103 mapped into a group grade without a change in base pay, twenty-one received adjustments and twelve required redesigned roles before final placement. The twenty-one adjustments added ₹74 lakh to annual pay cost. The twelve role decisions were completed over the following four months, with written responsibilities agreed with each colleague. These categories describe the initial mapping and should not be read as different levels of employee value. The process took longer than the sponsor’s original six-week expectation. That delay was a deliberate consequence of examining work rather than matching labels. It did not establish that everyone welcomed the acquisition or that future retention was secure. It did give managers and employees a more specific basis for discussing their place in the organisation. I would have separated the timetable for payroll continuity from the timetable for final role design more clearly at the outset. Combining them made some colleagues fear an immediate pay disruption when the unresolved question concerned their longer-term responsibilities.

Terrain

Where I know the ground.

  • Technical careers without compulsory management
  • Authority around quality responsibilities
  • Workforce planning for plant expansion
  • Reward design and unintended behaviour

Languages

Spoken along the way.

  • English
  • Telugu
  • Hindi

Fellow travellers

In their words.

Dev made the six-week delay and the overlap cost visible before we approved the staffing plan. That gave us a real expansion decision instead of a recruitment update with the operating consequences missing.
Meera SadvithanFictional CEO, Anvethra Pharmaceuticals; executive colleague since 2018
He asked us to define the specialist contribution before discussing the grade. The assessment remained a technical responsibility, while his team made the career and pay consequences clear to the people involved.
Kiran VelantriFictional development director, Anvethra Pharmaceuticals; partner in the 2021 specialist review

Dispatches

Notes from the road.

An invitation

Contact

I am open to a people-leadership or advisory mandate in a pharmaceutical business willing to examine the relationship between technical authority, careers and investment decisions. I would consider a first external board appointment with an appropriate induction and a clearly defined contribution. For speaking, I prefer a working discussion of one employment decision and its consequences to a general address on inspiration.

Open to
  • Board appointments
  • Advisory roles
  • Speaking invitations
  • Executive opportunities

office@devparameshvan.example